Forty Seven Inc, a clinical-stage US company focused on developing the next generation of transformational immuno-oncology treatments to enable a patient's immune system to defeat their cancer, today announced research collaborations with two major companies.
Financial terms of neither collaborations were disclosed.
The first is an agreement with Germany’s Merck KGaA (MRK: DE), to conduct a Phase Ib clinical trial combining Hu5F9-G4 with avelumab in patients with ovarian cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze